Table 3. Clinical findings and pathological nodal status.
| Clinical findings | n | Nodal metastasis | P | ||
|---|---|---|---|---|---|
| pN(+) | pN1 | pN2 | |||
| All patients | 325 | 38 (11.7%) | 21 | 17 | |
| cT factor (UICC version 8) | 0.12 | ||||
| cTis | 10 | 0 (0%) | 0 | 0 | |
| cT1mi | 11 | 0 (0%) | 0 | 0 | |
| cT1a | 51 | 3 (5.9%) | 2 | 1 | |
| cT1b | 146 | 17 (11.6%) | 9 | 8 | |
| cT1c | 107 | 18 (16.8%) | 10 | 8 | |
| cT factor (UICC version 7) | 0.64 | ||||
| cT1a | 146 | 15 (10.3%) | 9 | 6 | |
| cT1b | 151 | 21 (13.9%) | 12 | 9 | |
| cT2a/b | 28 | 2 (7.1%) | 0 | 2 | |
| cT1b/c sub-population (version 8) | 253 | 35 (13.8%) | 19 | 16 | |
| CT pattern | 0.31 | ||||
| Mixed GGO | 76 | 7 (9.2%) | 3 | 4 | |
| Solid type | 177 | 28 (15.8%) | 16 | 12 | |
| FDG-PET | 0.0085 | ||||
| SUVmax <1.9 | 68 | 3 (4.4%) | 2 | 1 | |
| SUVmax ≥1.9 | 185 | 32 (17.3%) | 17 | 15 | |
| Combined criteria | 0.0051 | ||||
| Mixed GGO & SUVmax <1.9 | 41 | 0 (0%) | 0 | 0 | |
| Solid type or SUVmax ≥1.9 | 212 | 35 (16.5%) | 19 | 16 | |
GGO, ground glass opacity; FDG-PET, fluorodeoxy glucose-positron emission tomography; SUVmax, maximum standardized uptake value.